ArticleOncogene2013
Reprogramming cancer cells: back to the future.
Article in Oncogene, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Lethal effects of mitochondria via microfluidics.Bioengineering & translational medicine · 2023Article
- Regulation of Cell Plasticity by Bromodomain and Extraterminal Domain (BET) Proteins: A New Perspective in Glioblastoma Therapy.International journal of molecular sciences · 2023Review
- Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis Bullosa.International journal of molecular sciences · 2020Article
- "Reprogram Enablement" as an Assay for Identifying Early Oncogenic Pathways by Their Ability to Allow Neoplastic Cells to Reacquire an Epiblast State.Stem cell reports · 2020Article
- Chasing Mavericks: The quest for defining developmental waves of hematopoiesis.Current topics in developmental biology · 2019Review
- Identification of protein kinase inhibitors to reprogram breast cancer cells.Cell death & disease · 2018Article
- Environmental Carcinogenesis and Transgenerational Transmission of Carcinogenic Risk: From Genetics to Epigenetics.International journal of environmental research and public health · 2018Article
- Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors.Journal of experimental & clinical cancer research : CR · 2018Article
- Article
- Expression of the miR-302/367 cluster in glioblastoma cells suppresses tumorigenic gene expression patterns and abolishes transformation related phenotypes.International journal of cancer · 2015Article
- Differentiation of human neuroblastoma cells toward the osteogenic lineage by mTOR inhibitor.Cell death & disease · 2015Article
- Role of mesenchymal stem cells in cell life and their signaling.World journal of stem cells · 2014Review
- Xenopatients 2.0: reprogramming the epigenetic landscapes of patient-derived cancer genomes.Cell cycle (Georgetown, Tex.) · 2014Article
- Cancer stem cells, a fuzzy evolving concept: a cell population or a cell property?Cell cycle (Georgetown, Tex.) · 2013Review
- Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).Cell cycle (Georgetown, Tex.) · 2013Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reprogramming healthy somatic cells into induced pluripotent stem cells (iPSCs) with four defined factors (Oct4, Sox2, c-Myc and Klf4) has been intensively investigated. However, reprogramming diseased cells such as cancer cells has fallen much behind. In this issue of Oncogene, Zhang et al. demonstrated that reprogrammed sarcoma cells with defined factors, as well as Nanog and Lin28, lost their tumorigenicity and dedifferentiated to mesenchymal stem cells (MSC) and hematopoietic stem cell (HSC)-like cells that can be terminally differentiated into mature connective tissues and red blood cells, suggesting sarcoma cells may be reversed back to a stage of common ancestor iPSC bifurcating for HSC and MSC ontogeny. It may, therefore, provide a novel strategy for cancer treatment via ancestor pluripotency induction.
Indexed as
Identifiers
22869153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.